Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma[1][2].
Molecular Weight:
152000 (average)
Purity:
99.69
CAS Number:
[1346452-25-2]
Target:
Antibody-Drug Conjugates (ADCs),Nectin-4
Application Notes:
ADC Related
* VAT and and shipping costs not included. Errors and price changes excepted
